Stroke is an increasing public health concern globally and its victims are particularly susceptible to cardiometabolic complications including dyslipidaemia, diabetes and obesity [1] . Metabolic syndrome (MetSyn) on the other hand is a term coined for the clustering of cardiovascular risk factors including diabetes mellitus, hypertriglyceridaemia, central obesity, increased low density lipoprotein cholesterol (LDL-C) and decreased high density lipoprotein cholesterol (HDL-C) [1] . MetSyn has been shown to increase risk for stroke and other cardiovascular diseases [2] . According to [3] [4] , metSyn confers 5-fold risk for type 2 diabetes and 2 to 3 fold increased risk for coronary heart disease and future ischaemic stroke [3] [4] . Prevalence of MetSyn is estimated to range from <10% to as high as 84% depending on the region and underlying condition of study [5] . Previous studies have indicated high prevalence of metabolic syndrome particularly among ischaemic stroke subjects [1] [6] .

In a case-control study among Iranians, 62% stroke subjects compared to 34% normal controls had metabolic syndrome. Also, in a case-control study involving 100 Ghanaian subjects with various cardiovascular diseases (stroke, coronary heart disease, peripheral arterial disease or heart failure) the prevalence of MetSyn was 54% [7] .

Whereas the cause of metabolic syndrome is uncertain and is believed to be multifactorial, the renin angiotensin aldosterone system (RAAS) has been found to play a significant role in its pathophysiology [1] . RAAS has been linked to components of MetSyn including obesity, dyslipidaemia, hypertension and insulin resistance [2] [8] .

The RAAS could be linked to cardiometabolic syndrome through possible interactions with atherogenic factors including vascular smooth muscle cells, mitogen-activated protein (MAP) kinase, intercellular adhesion molecule and oxidative stress (ICAM) 1 [9] [10] [11] .

Studies suggest that mineralocorticoid receptor (MR) antagonists could be important therapeutic agents in mitigating MetSyn and its complications [12] [13] .

However, data supporting the use of MR antagonists in ischaemic patients with the aim of preventing further metabolic defect is limited. There remains a paucity of data examining the relationship between the RAAS and the MetSyn in particularly ischaemic stroke. A better understanding of the association of RAAS and MetSyn may help in the management of ischaemic stroke subjects and thus minimize, if not entirely eradicate mortality from obesity, diabetes and hypertension [14] . Additionally, understanding the relationship between the RAAS and MetSyn in ischaemic strokes may help in the stratification and treatment of patients who may benefit substantially from RAAS blockade.

Normality of all continuous variables was tested using the D’Agostino-Pearson omnibus normality test. All non-parametric variables were normalized by log transformation before analysis. Continuous variables were expressed as mean ± Standard deviation (SD) and median (inter-quartile range) where appropriate. Categorical variables were expressed as frequency (n) and percentages (%). Associations of biochemical and clinical profile with metabolic syndrome among hypertensive were done using chi-square (χ²) tests or Fisher exact tests where appropriate. Three logistic regression models (A, B and C) were done with metabolic syndrome defined by H_MS criteria as dependent variable. Model A was unadjusted, model B was adjusted for age and gender whereas model C was adjusted for age, gender and hypertension. In all the models, lifestyle characteristics, BMI, lipid profile and RAAS parameters served as predictor variables. P-value less than 0.05was considered statistically significant for all analysis. IBM Statistical Package for the Social Sciences (SPSS) version 20.00 (SPSS Inc, Chicago, USA).

*Principal component of definition; ATP III = Adult Treatment Panel III; IDF = International Diabetes Federation; H_MS: Harmonization, IGT =  impaired, glucose tolerance; impaired fasting glycaemia; T2DM  = Type 2 diabetes mellitus; BMI = body mass index; WC = waist circumference; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; WC/CO: waist circumference/central obesity, WHR: waist-to-hip ratio, BMI: Body Mass Index, BP: Blood Pressure, TG: Triglycerides, HDL-C: High Density Lipoprotein Cholesterol, FBG: Fasting Blood Glucose.

The controls and stroke cases were age matched (p = 0.054) (Table 2). There were more males in the stroke subjects (62.1%) compared to the controls (47.5%) and differed significantly (p = 0.023). The stoke subjects had significantly higher mean plasma renin [(1.8 ± 0.1) pg/ml, p < 0.001], serum aldosterone [(2.9 ± 0.2) pg/ml, p < 0.001)] and ARR [(1.1 ±0.2), p < 0.001] compared to the controls [(1.4 ± 0.1) pg/ml, (2.3 ± 0.2) pg/ml and (0.9 ± 0.1)] respectively. Additionally, the case cohort had significantly larger average waist circumference (88.8 ± 14.6 vs 84.4 ± 8.2, p = 0.026) cm, waist-to-hip ratio (0.9 ± 0.1 vs 0.8 ± 0.1, p = 0.006) and body mass index (27.8 ± 4.7 vs 23.4 ± 5.1, p < 0.001) kg/m².

Per the NCEP-ATP, IDF and HMS criteria, metSyn prevalence of 8.3%, 9.2% and 6.7% respectively were recorded in the control subjects where as 50.0%, 71.2% and 71.2% respectively were recorded in the stroke subjects. Moreover, 36.4%, 12.1% and 13.6% of the stroke participants per NCEP-ATP, IDF and HMS criteria respectively had 2 clusters of metabolic syndrome components.

In the Bland Altman analysis above, there was an excellent agreement between NCEP_ATP versus IDF [bias = −0.107, 95%CI (−0.545 - 0.759)], NCEP_ATP versus H_MS [bias = −0.093, 95%CI (−0.525 - 0.710)], IDF versus H_MS [bias = −0.346, 95%CI (−0.317 - 0.317)] (Figure 1).

In the unadjusted model A, hypertension (OR = 9.2, p = 0.001), diabetes (OR = 5.8, p < 0.001), obesity (OR = 12.5, p < 0.001), third tertile renin (T₃) (OR = 9.1, p < 0.001), third tertile aldosterone (T₃) (OR = 3.6, p < 0.001) and high total cholesterol (OR = 2.4, p = 0.039) were significantly associated with metabolic syndrome compared to normotensives, non-diabetics, non-obese, lower renin- aldosterone quartiles and desirable total cholesterol values respectively. However, after adjusting for age, gender, diabetes and hypertension in model C, only obesity (aOR = 11.7, p = 0.004) and third tertile aldosterone (OR = 2.7, p = 0.008) were significantly associated with increased odds of metabolic syndrome.

Whereas plasma renin moderately correlated positively and significantly with WC (r = 0.493, p < 0.05) in metabolic syndrome subjects, it insignificantly

Categorical data are presented as a proportion with corresponding percentages in parenthesis. Continuous variables are presented as mean ± standard deviation. The proportions were compared using Fischer’s exact test. Continuous variables were compared using independent t-test and Mann Whitney U test where applicable. Mets: HS: hypertensive strokes, WC: waist circumference, HC: hip circumference, WHR: waist to hip ratio, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, PP: pulse pressure, HTN: hypertension, CVD: cardiovascular disease, ARR: aldosterone renin ratio, HDL: high density lipoprotein, LDL: low density lipoprotein, FBG: fasting blood glucose.

correlated with WC in non-metabolic syndrome subjects (r = 0.274, p > 0.05), as indicated in Table 5. Moreover, serum aldosterone negatively and significantly correlated with HDL-cholesterol (r = −0.317, p < 0.05) in metabolic syndrome subjects but was insignificant in non-metabolic syndrome subjects (r = −0.429, p > 0.05). In addition, serum aldosterone was significantly associated with increasing triglyceride in the metabolic syndrome group (r = 0.439, p < 0.05) but not in the non-metabolic syndrome group (r = 0.225, p > 0.05).

Metabolic syndrome (Metsyn) is known to increase the risk of adverse outcomes in stroke patients [24] [25] . Renin and aldosterone have been associated with the pathogenesis of obesity-related hypertension and weight loss has been shown to be complemented by reductions in plasma renin activity (PRA) and plasma aldosterone [26] . Albeit the role of the renin angiotensin aldosterone system in blood pressure regulation is well understood, its role in metabolic syndrome remains vague. In this study therefore, the relationships between the RAAS parameters and metabolic syndrome in some ischaemic stroke subjects were evaluated against data from apparently healthy cohorts within the same geographical boundary.

The study considered three different diagnostic criteria, NCEP, IDF and HSM. The overall degree of agreements between NCEP/IDF [bias = 0.107 (−0.545 - 0.760), r = 0.124 (−0.043 - 0.284)], NCEP/HMS [bias = 0.093 (−0.525 - 0.710), r = 0.118 (−0.049 - 0.278)] and IDF/H_MS [bias = −0.014 (−0.346 - 0.317), r = −0.022 (−0.187 - 0.145)] were excellent. However, each criteria gave different prevalence rates of 50.0%, 71.2% and 71.2% in the ischaemic group, 8.3%, 9.2%, and 6.7% in the normotensive control group per the NCEP-ATP, IDF and HMS criteria, respectively (Table 2 and Table 3).

In this study, MetSyn prevalence in the ischaemic stroke subjects defined by IDF and HMS criteria are higher than in previous studies conducted among Chinese acute stroke subjects (51.35%), ischaemic stroke subjects in India (60%) and Iran (62%) [6] [10] [27] . The discrepancies could be due to the differences in proportions of co-morbidities among study subjects. For instance, Mi et al. (2012) reported 87.5% hypertension prevalence in his subjects whereas 90.9% of the stroke subjects in this study were hypertensives. Sample size differences and inconsistencies in metabolic syndrome criteria could also have contributed to the differences in MetSyn prevalence.

The stroke subjects had significantly higher plasma renin, aldosterone and ARR compared to the control cohort (Table 2) suggesting that, the RAAS could have significant effect on cerebral circulation. In a review by [28] , angiotensin peptides and angiotensinergic neural pathways were found to be important in neural function. Though the distribution of angiotensin II receptor 1 (AT 1) coincides with some brain regions, neither renin nor angiotensin II and its related peptides nor renin pass readily from the blood into the brain interstitium [29] . Local intrinsic RAAS has therefore been proposed [30] .

Data are presented as a proportion with corresponding percentages in parenthesis. The proportions were compared using Fischer’s exact test. Mets: Metabolic Syndrome. HS: hypertensives with stroke, WHO: World Health Organization, NCEP-ATP III: National Cholesterol Education Program-Adult Treatment Panel III, IDF: International Diabetes Federation and H_MS: Harmonization.

This is apparent considering the fact that, anti-RAAS therapies have been proven to have cerebrovascular protective effects [31] [32] .

Moreover, high serum aldosterone was independently associated with metabolic syndromein this study (Table 4). To the best of our knowledge, this is perhaps the first time RAAS and its role in MetSyn has been studied specifically in stroke subjects. The effect of aldosterone on MetSyn in other conditions has however been studied. Higher significant levels were found in MetSyn participants compared to non-MetSyn subjects among patients with obstructive sleep apnea hypopnea syndrome (OSAHS) [33] . Similarly, a cross-sectional study conducted in 356 participants from 69 families of African descent Seychelles found aldosterone to be independently associated with metabolic syndrome [34] . Furthermore, Kidambi et al., (2007) found that plasma aldosterone levels and not PRA, were elevated in subjects with metabolic syndrome (P = 0.0002) in a study conducted in 182 hypertensive cases and 215 normotensive control Black Americans [26] . Besides increasing blood pressure, non-genomic effects of mineralocorticoid receptor (MR) activation by aldosterone has been found to also include activation of mitogen-activated protein (MAP) kinase and intercellular adhesion molecule (ICAM) 1 pathways which play key roles in atherosclerosis [35] . Aldosterone also increases the production of reactive oxygen species (ROS) through decreases in glucose-6-phosphate dehydrogenase activity and activation

Model A: unadjusted; Model B: adjusted for age and gender; Model C: adjusted for age, gender, diabetes and hypertension; Reference categories: Age (<40 years), healthy BMI (18.5 - 25.0 kg/m²), first tertile renin (<25.0 pg/ml), first tertile aldosterone (>504.0 pg/ml), desirable total cholesterol (<5.18 mmol/l), desirable triglyceride (<1.7 mmol/l), low HDL cholesterol (<1.0 mmol/l) and optimal LDL cholesterol (<2.59 mmol/l).

of NAD (P) H oxidase [36] . Mineralocorticoid receptor antagonists used in combination with ACE inhibitors and or angiotensin II blockers (ARBs) have shown beneficial effects in diabetic nephropathy [37] .

MR antagonists may therefore have positive effects on various components of the MetSyn through improving insulin sensitivity, reducing blood pressure, decreasing the pro-inflammatory state of MetSyn, and hence reduction in CVD occurrences [12] .

Aldosterone significantly correlated negatively with HDL-cholesterol (r = −0.317, p < 0.05) and positively with triglyceride concentration (r = 0.439, p < 0.05) in the metabolic syndrome participants (Table 5). Though the mechanism behind these correlations is not fully understood, aldosterone production has been shown to be stimulated by free fatty acids released from visceral adipose tissues [38] [39] . This is also consistent with the observation that drospirenone, an oral contraceptive with antimineralocorticoid properties, which is chemically related to spironolactone (a mineralocorticoid receptor blocker), significantly increased HDL cholesterol in young healthy women [40] .

In this study, increasing plasma renin was not independently associated with metabolic syndrome (Table 4). Contrary to this, among 29 volunteers with a range of risk factors studied, patients with more metabolic syndrome factor clustering including abdominal obesity and high blood pressure had significantly greater values for renin independent of dietary salt intake [41] . More recently, a prospective study involving 5301 African American adults, aged 21 - 94 years showed that log-transformed plasma renin levels were associated with Metsyn and its components in fully adjusted models [42] .

In this study, plasma renin levels significantly correlated negatively (r = −0.319, p < 0.05) with HDL-cholesterol levels. Concordance with this study, multivariate logistic regression analysis in a cross-sectional study showed that high PRA was independently associated high HDL-C [43] . Another cross-sec- tional study in 985 subjects with metSyn and 515 without metSyn showed that renin levels increased and correlated inversely with HDL [44] . Conversely, in a

*significant correlation (p < 0.05); WC, waist circumference; HC, hip circumference; WHR, waist-to-hip ratio; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; TC, total cholesterol; FBG, fasting blood glucose; TG, triglyceride.

cross-sectional study involving 80 males with central obesity, plasma renin activity had a positive correlation with HDL-cholesterol (r = 0.273; p = 0.014) [45] . The effects of anti-hypertensive drugs could be the reason behind the contrary views expressed.

We also witnessed a positive significant correlation between plasma renin and waist circumference (r = 0.493, p < 0.05). This is suggestive of renin playing key role in obesity and is in keeping with increased plasma angiotensinogen (a direct product of renin activity) in obese patients as compared with non-obese patients in a study by [46] . Moreover, an in vivo investigation of angiotensinogen (AGT) expression in adipose tissue and liver of Zucker rats during the onset of obesity showed adipocytes from obese rats displaying a significant increase in AGT content than in non-obese rats [47] .

Increased renin activity, a characteristic of an up regulated renin-angiotensin- aldosterone system has been described in patients with visceral obesity which improves with weight loss [9] . This has been explained by many as a result of the presence of local renin-angiotensin-aldosterone system in the adipose tissue which may play a significant role in the pathophysiology of obesity and of obesity-related hypertension [11] [48] .

Whilst a case can be made about the potential role of both renin and aldosterone in the pathophysiology of metabolic syndrome among ischaemic stroke patients in this study, the use of case-control study design limits their absolute cause and effect relationship. Moreover, plasma renin was measured as a concentration other than the more standardized measurement of its activity that is plasma renin activity (PRA). Therefore, further studies which employ robust study design involving follow-ups and measurement of PRA instead of concentration are warranted to fully understand the mechanism behind the RAAS and metabolic syndrome.

This study has demonstrated a high prevalence of metabolic syndrome among ischaemic stroke patients at the Komfo Anokye Teaching Hospital. Raised blood aldosterone was shown to be significantly associated with metabolic syndrome in the stroke subjects. These findings underpin the observations that increased aldosterone levels may exacerbate metabolic defects in people with ischaemic stroke. Therefore, combination of standard treatments with available mineralocorticoid receptor antagonists including spironolactone and eplerenone in ischaemic strokes may halt further vascular deterioration and re-occurrence of stroke. Other potent risk factors identified were high blood pressure, obesity and triglyceridaemia. Further studies with larger sample size and robust study design involving follow ups are warranted to fully understand the role RAAS plays in cardio-metabolic syndrome in ischaemic strokes.

The authors would like to acknowledge the management and staff of Department of Medicine, Komfo Anokye Teaching Hospital for allowing us carry out this work in their department. We are also grateful to all participants of this work for voluntarily agreeing to partake in this study.

The authors declare that there is no conflict of interest regarding the publication of this paper.

There was no funding for this work

Ethical approval (CHRPE/AP/377/15) for the study was obtained from the Committee on Human Research, Publication and Ethics (CHRPE) of the School of Medical Sciences (SMS), Kwame Nkrumah University of Science and Technology (KNUST) and Research and Development Unit KATH. Informed consent was obtained from all participants and participation was voluntary.

Francis Agyemang Yeboah contributed to the conception of the research idea, design data analysis and interpretation, paper drafting and revision. Benjamin Ackon Eghan contributed to the conception of the research idea, design, data analysis and interpretation, paper drafting and revision. Bernard Nkum contributed to the conception of the research idea, design, data collection, data analysis and interpretation, paper drafting and revision

Bright Amankwaa contributed to research design, patient recruitment, collection data analysis and interpretation, paper drafting and revision. Emmanuel Acheampong contributed to research design, patient recruitment and collection. Paul Nsiah contributed to the conception of the research idea, design and data collection. Lawrence Owusu and Perditer Okyere contributed to the conception of the research idea, design, and data collection. Emmanuella Batu Nsenba contributed to the research idea, design and data collection. Enoch Odame Anto contributed to research design, patient recruitment, collection data analysis and interpretation.

Yeboah, F.A., Nkum, B., Amankwaa, B., Eghan Jr., B.A., Acheampong, E., Nsiah, P., Okyere, P., Owusu, L., Nsenba, E.B. and Odame, E. Anto (2017) Metabolic Syndrome among Ischaemic Stroke Patients in Ghana: The Possible Role of Renin and Aldosterone. Open Access Library Journal, 4: e3952. https://doi.org/10.4236/oalib.1103952